| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec1c86a1be8e0c90734af692b8ff254b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a227b05abfae50f529cd3cf47818b61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d81d249afb5c3f92d20352cb2d8851fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a85274c9aff41f0f03260b1da19917d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_11f9c629cdeba64d7775d008fd78f281 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate |
1998-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2000-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d11547a39d7b40eeca44916df066a9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c1837f31a4754284c402d72e10019c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1188d8d4aa20fd2891aad9c0f20d578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c82f5b6d080f963925972314cc0fe108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13fd32e5b4d5ad22c17aefa91f92c9fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e86c5df39ba0970b981f355866fe12d6 |
| publicationDate |
2000-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2145226-C1 |
| titleOfInvention |
Method of selection of pharmacotherapy in duodenal ulcers |
| abstract |
FIELD: medicine, gastroenterology. SUBSTANCE: preparations are prescribed based on gastric secretion data. Microcirculation in of mucosa pyloro-duodenal region is assayed by endoscopy Doppler fluometry additionally. Actovegin is prescribed in the presence of increased secretion and decreased microcirculation and H2-antagonists of histamine receptors are prescribed additionally to patients of age before 50 years and omeprazole is prescribed to patients of age above 50 years. Only actovegin is prescribed to patients with normal secretion and decreased microcirculation. Preparations enhancing reparative processes are prescribed to patients with normal secretion and microcirculation. Method ensures to treat patients based on pathogenetic specificities of disease course using minimal amount of drugs. EFFECT: improved method of treatment. 3 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-017221-B1 |
| priorityDate |
1998-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |